Zhaohui Wang

Prof. Dr. Zhaohui Wang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2016 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
LYLianhua Yan
Lianhua Yan
FHFen Hu
Fen Hu
XYXiaofei Yan
Xiaofei Yan
YWYuzhen Wei
Yuzhen Wei
WMWenhan Ma
Wenhan Ma
ZWZhaohui Wang
Zhaohui Wang

20 June 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
TGTing Gan
Ting Gan
JHJing Hu
Jing Hu
WLWenhu Liu
Wenhu Liu
CLCui Li
Cui Li
QXQian Xu
Qian Xu
ZWZhaohui Wang
Zhaohui Wang
Background: Although previous observational studies have shown an association between anemia and cardiovascular disease (CVD), the underlying causal relationship between anemia and CVD remains uncertain. Methods and Results: We conducted a 2‐sample bidirectional Mendelian randomization (MR) study to assess the causal association between anemia and CVD. We extracted summary statistics data for anemia, heart failure (HF), coronary artery disease (CAD), atrial fibrillation, any stroke, and any ischemic stroke (AIS) from relevant published genome‐wide association studies. After rigorous quality control steps, independent single‐nucleotide polymorphisms for each disease were selected as instrumental variables. Inverse‐variance weighting was used as the primary method to estimate the causal association between anemia and CVD in the 2‐sample MR analysis. Simultaneously, we performed a series of multiple methods analyses (median weighting, maximum likelihood [MR robust adjusted profile score]), sensitivity analyses (Cochran's Q test and MR‐Egger intercept, leave‐one‐out test [MR pleiotropy residual sum and outlier]), instrumental variable strength evaluations ( F statistic), and statistic power estimates to verify the robustness and reliability of our results. Furthermore, the associations between anemia and CVD from different studies, including the UK Biobank and FinnGen studies, were combined by meta‐analysis. The MR analysis showed that genetically predicted anemia was significantly associated with HF risk at the Bonferroni‐corrected significance level (odds ratio [OR], 1.11 [95% CI, 1.04–1.18]; P =0.002) and was suggestively associated with CAD risk (OR, 1.11 [95% CI, 1.02–1.22]; P =0.020). However, the associations between anemia and atrial fibrillation, any stroke, or AIS were not statistically significant. In the reverse MR analysis, we found that genetic susceptibility to HF, CAD, and AIS was significantly associated with anemia risk. The ORs of HF, CAD, and AIS were 1.64 (95% CI, 1.39–1.94; P =7.60E‐09), 1.16 (95% CI, 1.08–1.24; P =2.32E‐05), and 1.30 (95% CI, 1.11–1.52; P =0.001), respectively. Genetically predicted atrial fibrillation was suggestively associated with anemia (OR, 1.06 [95% CI, 1.01–1.12]; P =0.015). Sensitivity analyses found weak evidence of horizontal pleiotropy and heterogeneity, which ensured the robustness and reliability of the results. Meta‐analysis also showed the statistically significant association between anemia and HF risk. Conclusions: Our study supports bidirectional causality between anemia and HF and significant associations between genetic predisposition to CAD and AIS with anemia, which contributes to the clinical management of both diseases.

1 May 2016 in Medicine
Verified
Journal Article
Open access
YSYaying Sun
Yaying Sun
SLShuai Lu
Shuai Lu
PZPeng Zhang
Peng Zhang
ZWZhaohui Wang
Zhaohui Wang
Jiwu ChenJiwu Chen
Jiwu Chen
To compare the effect of steroid injection and physiotherapy for patients with adhesive capsulitis of the shoulder (ACS).An electronic search was performed on Pubmed, Embase, and Cochrane library, and reference lists were also reviewed for randomized controlled trials (RCTs) comparing steroid injection and physiotherapy for patients with ACS. The quality of included studies were assessed using PEDro scale. Standardized mean differences (SMDs) and 95% confidence interval (CI) were used for comparisons. The primary outcome was functional improvement.Nine RCTs including 453 patients were identified. From 6-7 weeks to 24-26 weeks postintervention, no superiority was noted in favor of either steroid injection or physiotherapy for functional improvement (SMD 0.28; 95% CI -0.01-0.58; P = 0.06) or pain relief (SMD -0.10; 95% CI -0.70-0.50; P = 0.75). Steroid injection provided more improvement in passive external rotation at 24 to 26 weeks (3 studies, SMD 0.42; 95% CI 0.11-0.72; P = 0.007) but not at 6 to 7 weeks (4 studies, SMD 0.63; 95% CI 0.36-0.89; P = 0.32) or 12 to 16 weeks (3 studies, SMD -0.07; 95% CI -0.79-0.65; P = 0.85). Steroid injection was as safe as physiotherapy for patients with ACS (risk ratio 0.94; 95% CI 0.67-1.31).Both steroid injection and physiotherapy are equally effective for patients with ACS. One steroid injection might be the 1st choice for ACS. Results should be interpreted with caution due to the heterogeneity among the studies.

10 February 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JSJiangcheng Shu
Jiangcheng Shu
LHLizhi Hu
Lizhi Hu
YWYichen Wu
Yichen Wu
LCLong Chen
Long Chen
KHKai Huang
Kai Huang
MLMinglu Liang
Minglu Liang

1 May 2017 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YWYuzhen Wei
Yuzhen Wei
XYXiaofei Yan
Xiaofei Yan
LYLianhua Yan
Lianhua Yan
FHFen Hu
Fen Hu
WMWenhan Ma
Wenhan Ma
ZWZhaohui Wang
Zhaohui Wang
Cardiac fibrosis triggered by pressure overload represents one of the major challenges in the treatment of cardiovascular diseases. MicroRNA (miRNA/miR)‑155, a member of the small RNA family, has previously been demonstrated to be associated with cardiac inflammation. However, the effect of miR‑155 on cardiac fibrosis induced by angiotensin II (Ang II), particularly in cardiac fibroblasts, requires further investigation. The present study aimed to investigate the effect of miR‑155 in Ang II‑induced cardiac fibrosis using animal models and cardiac fibroblasts. Animal models were established in male miR‑155‑/‑ and wild‑type (WT) C57Bl/6J mice (10‑12 weeks old) by Ang II infusion using subcutaneously implanted minipumps. After 8 weeks of Ang II infusion, the results demonstrated that the deletion of miR‑155 in mice markedly ameliorated ventricular remodeling compared with WT mice, as demonstrated by restricted inflammatory responses, decreased heart size, improved cardiac function and reduced myocardial fibrosis. In vitro, overexpression of miR‑155 in cardiac fibroblasts led to significantly increased fibroblast to myofibroblast transformation. However, this effect was abrogated by miR‑155 silencing. In conclusion, the results of the present study indicate that genetic loss of miR‑155 in mice ameliorates cardiac fibrotic remodeling following pressure overload. Therefore, inhibiting miR‑155 may have potential as an adjunct to reduce cardiac inflammation in the treatment of cardiac fibrosis.

1 May 2016 in Medicine
Verified
Journal Article
Open access
SLShuai Lu
Shuai Lu
SGShizhe Guo
Shizhe Guo
FHFen Hu
Fen Hu
YGYushu Guo
Yushu Guo
LYLianhua Yan
Lianhua Yan
ZWZhaohui Wang
Zhaohui Wang
Vitamin D receptor (VDR) polymorphisms were indicated to be associated with coronary artery disease (CAD); however, published studies reported inconsistent results.The aim of this meta-analysis is to reach a more accurate estimation of the relationship between VDR genetic polymorphisms and CAD risk.Eligible studies were retrieved by searching PubMed, Embase, VIP, Wanfang and China National Knowledge Infrastructure databases. Included and excluded criteria were formulated. The case group was patients with CAD, and the control group was healthy subjects. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate VDR polymorphisms associations with CAD risk. Heterogeneity was evaluated by Q statistic and I statistic.Seven studies of a total of 2306 CAD patients and 4151 control subjects met the inclusion criteria. The pooled results from Taq1 showed increased risk in allelic model (OR = 1.14, 95% CI = 1.02-1.28), dominant model (OR = 1.21, 95% CI = 1.02-1.43), heterozygote model (OR = 1.19, 95% CI = 1.00-1.1.42), and homozygote model (OR = 1.27, 95% CI = 1.01-1.61). Besides, Fok1 T > C showed decreased risk in allelic model (OR = 0.81, 95% CI = 0.65-1.00) and Fok1 A > G also showed decreased risk in allelic model (OR = 0.67, 95% CI = 0.45-1.00) and recessive model (OR = 0.55, 95% CI = 0.31-0.97). In Caucasian subgroup, Bsm1showed increased risk in allelic model (OR = 1.23, 95% CI = 1.02-1.47), heterozygote model (OR = 1.20, 95% CI = 1.00-1.44), and homozygote model (OR = 1.22, 95% CI = 1.02-1.45). In CAD patients with type 2 diabetes mellitus (T2DM), Apa1showed a decreased risk in heterozygote model (OR = 0.80, 95% CI = 0.66-0.98); however, increased risk in recessive model (OR = 5.00, 95% CI = 2.74-9.13) was discovered in CAD patients without T2DM.The Fok1 polymorphism may play a protective role in CAD, and the possible protective role in Apa1 CA genotype in CAD patients with T2DM needs further studies. The Taq1 polymorphism is found to be associated with a significant increase in CAD risk based on our analysis; moreover, increased risk in Apa1 polymorphism in CAD patients without T2DM and Bsm1 polymorphism in Caucasian group is also detected.